Contributors: Okinawa Prefecture [Nahashi, Okinawa, Japan]; Okinawa Prefectural Chubu Hospital [Japan] - 沖縄県立中部病院; Nagasaki University; Institut Pasteur [Paris] (IP); Kumamoto University; National Center for Global Health and Medicine [Japan] (NCGM); Public Kumejima Hospital [Japan]; Okinawa Institute of Science and Technology Graduate University (OIST); Naha City Hospital [Japan] - 那覇市立病院; Queen Mary University of London (QMUL); Okinawa Prefectural Yaeyama Hospital [Japan] - 沖縄県立八重山病院; Okinawa Prefectural Miyako Hospital [Japan]; Rakuno Gakuen University [Japan] (RGU); Kyoto University; Nanbu Medical Center and Children's Medical Center [Japan]; Hokkaido University [Sapporo, Japan]; Tottori University; KM acknowledges support from the Japan Society for the Promotion of Science(JSPS) KAKENHI [Grant 20H03940 and 20KK0367], Japan Science and TechnologyAgency (JST) SICORP[JPMJSC21U4], and from the Leading Initiative for ExcellentYoung Researchers from the Ministry of Education, Culture, Sport, Science &Technology of Japan. YS acknowledges support from JSPS KAKENHI [21K10416].RM acknowledges support from JSPS KAKENHI [21K17250]. RO acknowledgessupport from the JST, CREST [Grant JPMJCR20H1]. MW was supported by thePlatform Project for Supporting Drug Discovery and Life Science Research (BINDS)from AMED [grant #JP18am0101076] and by direct funding from OIST.
نبذة مختصرة : We estimated the seroprevalence of anti-SARS-COV-2 IgG in different island groups in Okinawa. A cross-sectional sero-survey was repeated in three periods between July 2020 and February 2021. A total of 2683 serum samples were collected from six referral medical centers, each covering a separate region in Okinawa. In the main island, the seroprevalence was 0.0% (0/392, 95% CI: 0.0-0.9), 0.6% (8/1448, 0.2-1.1), and 1.4% (8/582, 0.6-2.7) at the 1st, 2nd, and 3rd sero-survey, respectively. In the remote islands, the seroprevalence was 0.0% (0/144, 95% CI: 0.0-2.5) and 1.6% (2/123, 0.2-5.8) at the 2nd and 3rd survey, respectively. The case detection ratio was 2.7 (95% CI: 1.3-5.3) in the main island and 2.8 (0.7-11.1) in the remote islands during the 3rd survey. The case detection ratio was the highest in people aged 20-29 years (8.3, 95% CI: 3.3-21.4) in the main island and in those aged 50-59 years (14.1, 2.1-92.7) in the remote islands, suggesting under-reporting of clinical cases by the surveillance system in these subgroups. A sero-survey during an emerging infectious disease epidemic can be useful for validating the reliability of the surveillance system by providing the case detection ratio.
Processing Request
No Comments.